Document Detail


Helicobacter pylori eradication in children and adolescents by a once daily 6-day treatment with or without a proton pump inhibitor in a double-blind randomized trial.
MedLine Citation:
PMID:  15274666     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIM: To evaluate two simplified Helicobacter pylori eradication treatment alternatives for children and adolescents. METHODS: Study subjects were identified by enzyme-linked immunosorbent assay and immunoblot in a family screening project. Helicobacter pylori infected 10-21 year olds were offered treatment, individuals with abdominal pain underwent upper endoscopy and those with peptic ulcers were excluded. Participants were randomized to either azithromycin 500 mg daily and tinidazole 500 mg two tablets daily in combination with lansoprasole 30 mg daily for 6 days (ATL-group) or with placebo (ATP-group). Urea Breath Test was performed at inclusion and after a minimum of 6 weeks after end of therapy. RESULTS: In total, 131 individuals were randomized, of whom 31 (24%) had undergone upper endoscopy. Full compliance was achieved in 93% (122 of 131). The intention-to-treat eradication rate was 67% (44 of 66) and 58% (38 of 65) for the ATL- and the ATP-group, respectively. CONCLUSION: The double-blind randomized clinical trial did not identify a simplified, successful once daily H. pylori treatment for children and adolescents. Thus, twice daily proton pump inhibitor (PPI)-based triple therapies for 7 days remain as the choice of treatment in children. Further, powerful and controlled studies are needed to elucidate the best treatment strategies for H. pylori eradication in this age group.
Authors:
Y Tindberg; T H Casswall; M Blennow; C Bengtsson; M Granström; M Sörberg
Related Documents :
22156316 - Long-term risk of leukaemia or cardiomyopathy after mitoxantrone therapy for multiple s...
22113766 - Post percutaneous coronary intervention antiplatelet therapy: current perceptions, pros...
22181066 - Pulse cyclophosphamide induction treatment in thai children with diffuse proliferative ...
21895786 - Use of dermasilk briefs in recurrent vulvovaginal candidosis: safety and effectiveness.
1543396 - Improvement in survival from typhoid ileal perforation. results of 221 operative cases.
24987366 - 25-gauge vitrectomy combined with half-fluence photodynamic therapy for the treatment o...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Alimentary pharmacology & therapeutics     Volume:  20     ISSN:  0269-2813     ISO Abbreviation:  Aliment. Pharmacol. Ther.     Publication Date:  2004 Aug 
Date Detail:
Created Date:  2004-07-27     Completed Date:  2004-12-16     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8707234     Medline TA:  Aliment Pharmacol Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  295-302     Citation Subset:  IM    
Affiliation:
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
2-Pyridinylmethylsulfinylbenzimidazoles
Adolescent
Adult
Azithromycin / administration & dosage
Breath Tests
Child
Double-Blind Method
Drug Administration Schedule
Drug Resistance
Drug Therapy, Combination / administration & dosage*
Female
Helicobacter Infections / drug therapy*
Helicobacter pylori*
Humans
Male
Omeprazole / administration & dosage*,  analogs & derivatives*
Patient Compliance
Proton Pumps / antagonists & inhibitors*
Tinidazole / administration & dosage
Treatment Outcome
Chemical
Reg. No./Substance:
0/2-Pyridinylmethylsulfinylbenzimidazoles; 0/Proton Pumps; 103577-45-3/lansoprazole; 19387-91-8/Tinidazole; 73590-58-6/Omeprazole; 83905-01-5/Azithromycin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Increased thrombin generation and circulating levels of tumour necrosis factor-alpha in patients wit...
Next Document:  Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their ...